Press release
Biosimilars Market to Surpass US$ 171.79 Billion by 2033, Driven by Rapid FDA Approvals and Affordable Biologic Alternatives
Biosimilars Market
Get a Free Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.datamintelligence.com/download-sample/biosimilars-market?utm_source=OpenPR&utm_campaign=Onkar
The global market is being fueled by a surge in biosimilar approvals, falling production costs, and strong support from healthcare regulators. The increasing use of biologics in oncology, autoimmune diseases, diabetes, and hematology has created an urgent need for cost-effective alternatives, where biosimilars are bridging the affordability gap. North America remains the largest market, driven by the U.S. FDA's accelerated approval process and growing adoption by major healthcare systems, while Asia-Pacific is the fastest-growing region with expanding clinical research and local manufacturing capabilities.
Key Highlights from the Report
➤ Market value projected to rise from US$ 22.58 billion in 2024 to US$ 171.79 billion by 2033, growing at 25.5% CAGR.
➤ Over 70 biosimilars approved in the U.S. to date, strengthening North America's leadership in biosimilar development.
➤ Oncology segment dominates with increasing biosimilars for bevacizumab, rituximab, and trastuzumab.
➤ Lower pricing and expanded access to biologic therapies driving adoption across emerging markets.
➤ New FDA approvals in 2024-2025 include biosimilars like Omlyclo (omalizumab), Steqeyma (ustekinumab), and Pavblu (aflibercept).
➤ Immunogenicity and cost of large-scale manufacturing remain key market challenges.
Market Segmentation
The global biosimilars market is segmented by product type, application, and region.
Application: Oncology Dominates Global Share
The oncology segment holds the largest share in the biosimilars market, supported by a rising global cancer burden and the growing need for affordable therapeutic options. According to the World Health Organization (WHO), cancer remains one of the leading causes of death, with nearly 20 million new cases in 2022 and projected cases expected to reach 29.9 million by 2040. Biosimilars offer a cost-effective alternative for expensive cancer therapies.
Several oncology-based biosimilars-such as those for Herceptin (trastuzumab), Avastin (bevacizumab), and Rituxan (rituximab)-have received approvals from the FDA and European Medicines Agency (EMA), solidifying market confidence. The expanded use of biosimilars for biologics like Eylea, Stelara, and Prolia continues to enhance the oncology segment's revenue contribution.
Product Pipeline: Expanding Therapeutic Reach
Biosimilars are now approved across a wide range of treatments, including diabetes (insulins), autoimmune diseases (adalimumab, infliximab), and hematologic conditions (filgrastim). The FDA-approved Omlyclo as an interchangeable biosimilar to Xolair in March 2025, marking a breakthrough for asthma and allergy treatment biosimilars. New entries like Steqeyma and Yesintek for Stelara continue to diversify the market landscape.
Get Customization in the Report as Per Your Business Requirements: https://www.datamintelligence.com/customize/biosimilars-market?utm_source=OpenPR&utm_campaign=Onkar
Regional Insights
North America: Global Market Leader
North America dominates the global biosimilars market, fueled by rapid FDA approvals, a robust legal framework under the Biologics Price Competition and Innovation Act (BPCI Act), and major pharmaceutical players. The U.S. FDA's 71 approved biosimilars demonstrate its proactive approach to regulating and accelerating market entry. Amgen, Pfizer, and Celltrion are leading the charge, with flagship products such as Amjevita (adalimumab), Inflectra (infliximab), and STEQEYMA (ustekinumab-stba) now available in the region.
Asia-Pacific: Fastest-Growing Market
Asia-Pacific is emerging as the fastest-growing market for biosimilars, aided by strategic collaborations and strong investment in R&D. Countries such as India, China, South Korea, and Japan are advancing domestic biosimilar production to reduce dependency on imports. India's Biocon Biologics and Dr. Reddy's Laboratories are at the forefront of global biosimilar innovation, supporting healthcare affordability across Asia and Africa.
Market Dynamics
Market Drivers
The broader adoption of biosimilars across oncology, immunology, and chronic diseases is driving exponential growth. Regulatory clarity from organizations like the FDA and EMA promotes industry competition, creating pathways for cost-effective and timely approvals.
Market Restraints
Immunogenicity and safety concerns remain barriers to wider adoption. Patient responses to biosimilars may vary slightly due to molecular structure differences during manufacturing, raising long-term safety considerations. Moreover, the high cost of production and stringent regulatory requirements constrain entry for smaller manufacturers.
Market Opportunities
As patents for blockbuster biologics continue to expire, emerging biopharmaceutical companies have opportunities to launch biosimilars across new therapeutic categories. Technological advances in purification, analytical testing, and recombinant DNA technologies also promise higher manufacturing efficiency and global competitiveness.
Purchase This Exclusive Report at Just USD 4457 Only: https://www.datamintelligence.com/buy-now-page?report=biosimilars-market?utm_source=OpenPR&utm_campaign=Onkar
Reasons to Buy the Report
✔ Detailed analysis of biosimilar trends, emerging therapeutic segments, and competitive dynamics.
✔ Insights into regulatory pathways driving biosimilar approvals globally.
✔ Comprehensive overview of key therapeutic categories, including oncology and autoimmune diseases.
✔ Regional insights highlighting North America's leadership and Asia-Pacific's high-growth potential.
✔ Evaluation of investment opportunities and market challenges for new entrants.
Frequently Asked Questions (FAQs)
◆ How big is the biosimilars market in 2024?
◆ What is the expected CAGR for the global biosimilars market through 2033?
◆ Which region leads the global biosimilars market?
◆ Which therapeutic segment holds the largest share in the biosimilars industry?
◆ Who are the key players operating in the global biosimilars market?
Company Insights
Amgen Inc.
Pfizer Inc.
Sandoz Group AG
Teva Pharmaceuticals USA, Inc.
Biogen
Biocon Biologics Inc.
Boehringer Ingelheim International GmbH
Samsung Bioepis
Dr. Reddy's Laboratories Ltd.
Fresenius Kabi AG
Recent Developments
March 2025: Celltrion received FDA approval for OMLYCLO (omalizumab-igec), the first interchangeable biosimilar to Xolair, broadening treatment accessibility for asthma and allergic disorders.
December 2024: Celltrion gained FDA approval for STEQEYMA (ustekinumab-stba), reinforcing its standing in the immunology biosimilars segment.
Conclusion
The Global Biosimilars Market is undergoing unprecedented expansion as pharmaceutical companies capitalize on patent expiries, technological progress, and favorable regulatory reforms. North America's well-defined approval pathways continue to set benchmarks for quality and accessibility, while Asia-Pacific's cost-efficient manufacturing capabilities are expanding the global supply network. As biosimilars become integral to healthcare systems worldwide, their growing affordability and therapeutic diversity will redefine patient access to biologic medications through 2033.
Contact Us
Mr. Sai Kiran
DataM Intelligence 4market Research LLP Ground floor
DSL Abacus IT Park, Industrial Development Area
Uppal, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com
Visit Our Website: https://www.datamintelligence.com
About Us
DataM Intelligence 4Market Research is a comprehensive market intelligence platform offering syndicated and customized reports along with expert consulting across multiple industries, including chemicals, healthcare, agriculture, food & beverages, and more. With extensive experience and a strategy-focused approach, DataM provides businesses and individuals with reliable market insights, statistical forecasts, and personalized research solutions to help them make informed decisions and successfully bring innovations to market.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Biosimilars Market to Surpass US$ 171.79 Billion by 2033, Driven by Rapid FDA Approvals and Affordable Biologic Alternatives here
News-ID: 4217990 • Views: …
More Releases from DataM Intelligence 4Market Research LLP
United States Indoor Plants Market (2024-2031): AI-Driven Greenhouse Innovations …
The Indoor Plants Market will exhibit a CAGR of 4.94% during the forecast period, 2024-2031.
The Indoor Plants Market includes ornamental and air-purifying plants used in homes, offices, and public spaces. Growth is fueled by wellness awareness, urban living, and interior décor trends. E-commerce and DIY gardening boost accessibility. Smart pots and hydroponic systems enhance maintenance efficiency. Consumers prefer eco-friendly and low-maintenance plant varieties. Sustainability and mental well-being continue to drive…
Heart Transplant Market Poised for Steady Growth Driven by Medical Innovations a …
According to DataM Intelligence, the Global Heart Transplant Market is experiencing notable growth, driven by advancements in surgical methods, artificial heart development, and improved access to donor organs. The market continues to gain traction as heart transplantation remains a vital treatment option for patients suffering from end-stage heart failure and severe cardiac diseases. Innovations in immunosuppressive therapies and organ preservation techniques have improved post-transplant survival rates and quality of life,…
Sustainable Aviation Fuel Market Size to Reach USD 3.58 Billion by 2030, Driven …
According to DataM Intelligence, the Global Sustainable Aviation Fuel (SAF) Market was valued at USD 320.8 million in 2022 and is projected to reach USD 3,581.0 million by 2030, expanding at a striking CAGR of 35.2% during the forecast period (2024-2031). The market's rapid expansion is being fueled by growing global efforts to decarbonize the aviation industry, advancements in fuel processing technologies, and government-backed initiatives promoting low-carbon energy solutions.
Get a…
Ultra-High Strength Steel Market 2025 | Industry Developments, Future Growth, Sh …
The ultra-high strength steel market is estimated to grow at a CAGR of 7.3% during the forecast period (2025-2032) from its current value of US$ 16,527 million in 2024 to reach a value of US$ 26,999.19 million in 2031.
📌 Download Sample Report to Identify Emerging Deals & Opportunities in the Ultra-High Strength Steel Market Landscape:- https://datamintelligence.com/download-sample/ultra-high-strength-steel-market?kb
☛ Ultra-High Strength Steel Market Recent Developments 2025:
United States: Recent Industry Developments
✅ In July…
More Releases for Biosimilars
Transformative Trends Impacting the Biosimilars Market Landscape: Innovative Pro …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Biosimilars Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The dimensions of the biosimilars market have been rapidly expanding over the last couple of years. The escalation, from a worth of $18.65 billion in 2024 to an estimated value of $21.95 billion in 2025, denotes…
Evolving Market Trends In The Biosimilars Industry: Innovative Product Launched …
The Biosimilars Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Biosimilars Market Size During the Forecast Period?
The dimension of the biosimilars market has experienced substantial expansion in the last few years. The market value, which was at $18.65 billion in 2024,…
Prominent Rituximab Biosimilars Market Trend for 2025: Collaborative Innovations …
Which drivers are expected to have the greatest impact on the over the rituximab biosimilars market's growth?
The rituximab biosimilars market is anticipated to grow due to the projected increase in non-Hodgkin's lymphoma (NHL) cases. NHL is a cancer that originates in the white blood cells and lymphocytes, which are integral parts of the body's immune system. For example, the American Cancer Society, a cancer advocacy group based in the US,…
Global Oncology Biosimilars Market | Global Oncology Biosimilars Industry | Onco …
The oncology biosimilars market involves of sales of medicine and drug interrelated products for cancer treatment. Biosimilars are pharmaceuticals which are produced using cell lines and are fashionable to the manufacturer. The manufacturing of such cell line processes is a multipart and time-consuming procedure.
According to the report analysis, ‘Oncology Biosimilars Market Global Report 2020-30’ states that the worldwide oncology biosimilars market was worth USD 2990.34 million in 2019. It is…
Global Biosimilars Market | Global Biosimilars Industry | Global Biosimilars Mar …
The biosimilars market involves of sales of biosimilars and associated services that are cast-off to treat chronic sicknesses such as diabetes, arthritis, and cancer. The Biosimilars are pharmaceuticals that are produced using cell lines and offers no clinical difference as linked to biologics. The Biosimilars are made once the patent of biologics is deceased.
According to the report analysis, ‘Biosimilars Market Global Report 2020-30’ states that the worldwide biosimilars market was…
Insulin Biosimilars Market, by Biosimilar Type Rapid-acting Biosimilars, Long-ac …
Diabetes is a group of metabolic disease characterized by high blood sugar level due to inadequate secretion of insulin. Common symptoms of diabetes include increased hunger, tiredness, weight loss, and excessive thirst and urination. The prevalence of diabetes is increasing, in turn, boosting demand for insulin biosimilar. For instance, according the World Health Organization (WHO) report in 2014, globally around 422 million adults were living with diabetes and 1.5 million…
